BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30670599)

  • 1. Diagnosis and Treatment Monitoring of a Patient with Gastrointestinal Stromal Tumor by Next-Generation Sequencing and Droplet Digital Polymerase Chain Reaction Assay of a PDGFRA Mutation in Plasma-Derived Cell-Free Tumor DNA.
    Boonstra PA; Ter Elst A; Tibbesma M; Gietema JA; Schuuring E; Reyners AKL
    Oncologist; 2019 Jun; 24(6):e387-e390. PubMed ID: 30670599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Highly Sensitive Digital Droplet PCR for Detection of cKIT Mutations in Circulating Free DNA That Mediate Resistance to TKI Treatment for Gastrointestinal Stromal Tumor (GIST).
    Rassner M; Waldeck S; Follo M; Jilg S; Philipp U; Jolic M; Wehrle J; Jost PJ; Peschel C; Illert AL; Duyster J; Scherer F; von Bubnoff N
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST).
    Jilg S; Rassner M; Maier J; Waldeck S; Kehl V; Follo M; Philipp U; Sauter A; Specht K; Mitschke J; Lange T; Bauer S; Jost PJ; Peschel C; Duyster J; Gaiser T; Hohenberger P; von Bubnoff N
    Int J Cancer; 2019 Oct; 145(8):2292-2303. PubMed ID: 30882891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors.
    Serrano C; Vivancos A; López-Pousa A; Matito J; Mancuso FM; Valverde C; Quiroga S; Landolfi S; Castro S; Dopazo C; Sebio A; Virgili AC; Menso MM; Martín-Broto J; Sansó M; García-Valverde A; Rosell J; Fletcher JA; George S; Carles J; Arribas J
    BMC Cancer; 2020 Feb; 20(1):99. PubMed ID: 32024476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.
    Gao J; Li J; Li Y; Li Z; Gong J; Wu J; Liu N; Dong B; Qi C; Li J; Shen L
    Oncotarget; 2016 May; 7(21):30241-9. PubMed ID: 26848617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
    Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
    Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
    Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
    Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy.
    Martínez-Marín V; Maki RG
    Gastroenterol Clin North Am; 2016 Sep; 45(3):477-86. PubMed ID: 27546844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Unexpected Response to Imatinib in a "Wild-Type" Gastrointestinal Stromal Tumor.
    Gheysen M; Vander Borght S; Lehnert S; Vanslembrouck R; Vanden Bempt I; Schöffski P
    Oncol Res Treat; 2020; 43(9):470-473. PubMed ID: 32640452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
    Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
    Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing gastrointestinal stromal tumors and evaluating neoadjuvant imatinib by sequencing of endoscopic ultrasound-biopsies.
    Hedenström P; Nilsson B; Demir A; Andersson C; Enlund F; Nilsson O; Sadik R
    World J Gastroenterol; 2017 Aug; 23(32):5925-5935. PubMed ID: 28932084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor.
    Wada N; Kurokawa Y; Takahashi T; Hamakawa T; Hirota S; Naka T; Miyazaki Y; Makino T; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
    Oncology; 2016; 90(2):112-7. PubMed ID: 26779618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor.
    Kang G; Bae BN; Sohn BS; Pyo JS; Kang GH; Kim KM
    Target Oncol; 2015 Dec; 10(4):597-601. PubMed ID: 25735500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of mutant free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor harboring activating mutations of CKIT or PDGFRA.
    Maier J; Lange T; Kerle I; Specht K; Bruegel M; Wickenhauser C; Jost P; Niederwieser D; Peschel C; Duyster J; von Bubnoff N
    Clin Cancer Res; 2013 Sep; 19(17):4854-67. PubMed ID: 23833305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research advance of liquid biopsy in gastrointestinal stromal tumors].
    Sun JY; Gao XD; Shen KT
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):917-921. PubMed ID: 32927519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
    Farag S; Somaiah N; Choi H; Heeres B; Wang WL; van Boven H; Nederlof P; Benjamin R; van der Graaf W; Grunhagen D; Boonstra PA; Reyners AK; Gelderblom H; Steeghs N
    Eur J Cancer; 2017 May; 76():76-83. PubMed ID: 28284172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
    Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cells as a prognostic and predictive marker in gastrointestinal stromal tumors: a prospective study.
    Li Q; Zhi X; Zhou J; Tao R; Zhang J; Chen P; Røe OD; Sun L; Ma L
    Oncotarget; 2016 Jun; 7(24):36645-36654. PubMed ID: 27153560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.
    Ihle MA; Huss S; Jeske W; Hartmann W; Merkelbach-Bruse S; Schildhaus HU; Büttner R; Sihto H; Sundby Hall K; Eriksson M; Reichardt P; Joensuu H; Wardelmann E
    PLoS One; 2018; 13(2):e0193048. PubMed ID: 29451912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.